-
1
-
-
0032748385
-
Antitumor activity of thalidomide in refractory multiple myeloma
-
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
-
(1999)
N Engl J Med
, vol.341
, pp. 1565-1571
-
-
Singhal, S.1
Mehta, J.2
Desikan, R.3
Ayers, D.4
Roberson, P.5
Eddlemon, P.6
-
2
-
-
69949096727
-
Mechanism of action of lenalidomide in hematological malignancies
-
Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.
-
(2009)
J Hematol Oncol
, vol.2
, pp. 36
-
-
Kotla, V.1
Goel, S.2
Nischal, S.3
Heuck, C.4
Vivek, K.5
Das, B.6
-
3
-
-
84885367692
-
-
Chanan-Khan AA, Immunomodulating Drugs for the Treatment of Cancer. Philadelphia Lippincott, Williams & Wilkins
-
Swaika A, Paulus A, Chanan-Khan A. Pomalidomide in cancer therapy (pp. 253-265). In Chanan-Khan AA, Immunomodulating Drugs for the Treatment of Cancer. Philadelphia: Lippincott, Williams & Wilkins.
-
Pomalidomide in Cancer Therapy
, pp. 253-265
-
-
Swaika, A.1
Paulus, A.2
Chanan-Khan, A.3
-
4
-
-
33947243663
-
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
-
DOI 10.1200/JCO.2005.05.0401
-
Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343-5349. (Pubitemid 46623164)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.34
, pp. 5343-5349
-
-
Chanan-Khan, A.1
Miller, K.C.2
Musial, L.3
Lawrence, D.4
Padmanabhan, S.5
Takeshita, K.6
Porter, C.W.7
Goodrich, D.W.8
Bernstein, Z.P.9
Wallace, P.10
Spaner, D.11
Mohr, A.12
Byrne, C.13
Hernandez-Ilizaliturri, F.14
Chrystal, C.15
Starostik, P.16
Czuczman, M.S.17
-
5
-
-
0033532557
-
Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
-
DOI 10.1016/S0960-894X(99)00250-4, PII S0960894X99002504
-
Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999; 9: 1625-1630. (Pubitemid 29274209)
-
(1999)
Bioorganic and Medicinal Chemistry Letters
, vol.9
, Issue.11
, pp. 1625-1630
-
-
Muller, G.W.1
Chen, R.2
Huang, S.-Y.3
Corral, L.G.4
Wong, L.M.5
Patterson, R.T.6
Chen, Y.7
Kaplan, G.8
Stirling, D.I.9
-
6
-
-
1942534043
-
The evolution of thalidomide and its IMiD derivatives as anticancer agents
-
Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-322. (Pubitemid 38525287)
-
(2004)
Nature Reviews Cancer
, vol.4
, Issue.4
, pp. 314-322
-
-
Bartlett, J.B.1
Dredge, K.2
Dalgleish, A.G.3
-
7
-
-
74249089972
-
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
-
Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24: 22-32.
-
(2010)
Leukemia
, Issue.24
, pp. 22-32
-
-
Quach, H.1
Ritchie, D.2
Stewart, A.K.3
Neeson, P.4
Harrison, S.5
Smyth, M.J.6
-
8
-
-
0033168605
-
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α
-
Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-386. (Pubitemid 29295864)
-
(1999)
Journal of Immunology
, vol.163
, Issue.1
, pp. 380-386
-
-
Corral, L.G.1
Haslett, P.A.J.2
Muller, G.W.3
Chen, R.4
Wong, L.-M.5
Ocampo, C.J.6
Patterson, R.T.7
Stirling, D.I.8
Kaplan, G.9
-
9
-
-
0035412366
-
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
-
Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
-
(2001)
Blood
, vol.98
, pp. 210-216
-
-
Davies, F.E.1
Raje, N.2
Hideshima, T.3
Lentzsch, S.4
Young, G.5
Tai, Y.T.6
-
10
-
-
27144458424
-
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-θ activation and enhancing the DNA-binding activity of AP-1 but not NF-κB, OCT-1, or NF-AT
-
DOI 10.1089/jir.2005.25.604
-
Payvandi F, Wu L, Naziruddin SD, Haley M, Parton A, Schafer PH et al. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. J Interferon Cytokine Res 2005; 25: 604-616. (Pubitemid 41507816)
-
(2005)
Journal of Interferon and Cytokine Research
, vol.25
, Issue.10
, pp. 604-616
-
-
Payvandi, F.1
Wu, L.2
Naziruddin, S.D.3
Haley, M.4
Parton, A.5
Schafer, P.H.6
Chen, R.S.7
Muller, G.W.8
Hughes, C.C.W.9
Stirling, D.I.10
-
11
-
-
0038476461
-
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs
-
DOI 10.1124/jpet.102.048496
-
Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003; 305: 1222-1232. (Pubitemid 36618002)
-
(2003)
Journal of Pharmacology and Experimental Therapeutics
, vol.305
, Issue.3
, pp. 1222-1232
-
-
Schafer, P.H.1
Gandhi, A.K.2
Loveland, M.A.3
Chen, R.S.4
Man, H.-W.5
Schnetkamp, P.P.M.6
Wolbring, G.7
Govinda, S.8
Corral, L.G.9
Payvandi, F.10
Muller, G.W.11
Stirling, D.I.12
-
12
-
-
19944430437
-
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application
-
Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005; 128: 192-203.
-
(2005)
Br J Haematol
, vol.128
, pp. 192-203
-
-
Hayashi, T.1
Hideshima, T.2
Akiyama, M.3
Podar, K.4
Yasui, H.5
Raje, N.6
-
13
-
-
23844435619
-
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
-
DOI 10.1158/1078-0432.CCR-05-0577
-
Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005; 11: 5984-5992. (Pubitemid 41170330)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.16
, pp. 5984-5992
-
-
Hernandez-Ilizaliturri, F.J.1
Reddy, N.2
Holkova, B.3
Ottman, E.4
Czuczman, M.S.5
-
14
-
-
0037093854
-
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity
-
Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002; 168: 4914-4919. (Pubitemid 34495953)
-
(2002)
Journal of Immunology
, vol.168
, Issue.10
, pp. 4914-4919
-
-
Dredge, K.1
Marriott, J.B.2
Todryk, S.M.3
Muller, G.W.4
Chen, R.5
Stirling, D.I.6
Dalgleish, A.G.7
-
15
-
-
67349107194
-
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
-
Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58: 1033-1045.
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 1033-1045
-
-
Galustian, C.1
Meyer, B.2
Labarthe, M.C.3
Dredge, K.4
Klaschka, D.5
Henry, J.6
-
16
-
-
67651111993
-
Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases
-
Xu Y, Li J, Ferguson GD, Mercurio F, Khambatta G, Morrison L et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 2009; 114: 338-345.
-
(2009)
Blood
, vol.114
, pp. 338-345
-
-
Xu, Y.1
Li, J.2
Ferguson, G.D.3
Mercurio, F.4
Khambatta, G.5
Morrison, L.6
-
17
-
-
33645736007
-
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
-
Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006; 107: 3098-3105.
-
(2006)
Blood
, vol.107
, pp. 3098-3105
-
-
Anderson, G.1
Gries, M.2
Kurihara, N.3
Honjo, T.4
Anderson, J.5
Donnenberg, V.6
-
18
-
-
54049156803
-
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
-
Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22: 1925-1932.
-
(2008)
Leukemia
, vol.22
, pp. 1925-1932
-
-
Breitkreutz, I.1
Raab, M.S.2
Vallet, S.3
Hideshima, T.4
Raje, N.5
Mitsiades, C.6
-
19
-
-
0034331194
-
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
-
Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
-
(2000)
Blood
, vol.96
, pp. 2943-2950
-
-
Hideshima, T.1
Chauhan, D.2
Shima, Y.3
Raje, N.4
Davies, F.E.5
Tai, Y.T.6
-
20
-
-
36849024949
-
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo
-
DOI 10.1111/j.1365-2141.2007.06841.x
-
Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140: 36-45. (Pubitemid 350233246)
-
(2008)
British Journal of Haematology
, vol.140
, Issue.1
, pp. 36-45
-
-
Reddy, N.1
Hernandez-Ilizaliturri, F.J.2
Deeb, G.3
Roth, M.4
Vaughn, M.5
Knight, J.6
Wallace, P.7
Czuczman, M.S.8
-
21
-
-
60449115552
-
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions
-
Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009; 77: 78-86.
-
(2009)
Microvasc Res
, vol.77
, pp. 78-86
-
-
Lu, L.1
Payvandi, F.2
Wu, L.3
Zhang, L.H.4
Hariri, R.J.5
Man, H.W.6
-
22
-
-
20444422917
-
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
-
DOI 10.1182/blood-2004-11-4201
-
Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, Rosato R et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 2005; 105: 4784-4791. (Pubitemid 40807304)
-
(2005)
Blood
, vol.105
, Issue.12
, pp. 4784-4791
-
-
Ladetto, M.1
Vallet, S.2
Trojan, A.3
Dell'Aquila, M.4
Monitillo, L.5
Rosato, R.6
Santo, L.7
Drandi, D.8
Bertola, A.9
Falco, P.10
Cavallo, F.11
Ricca, I.12
De Marco, F.13
Mantoan, B.14
Bode-Lesniewska, B.15
Pagliano, G.16
Francese, R.17
Rocci, A.18
Astolfi, M.19
Compagno, M.20
Mariani, S.21
Godio, L.22
Marino, L.23
Ruggeri, M.24
Omede, P.25
Palumbo, A.26
Boccadoro, M.27
more..
-
23
-
-
23044449530
-
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
-
DOI 10.1158/1078-0432.CCR-05-0213
-
Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005; 11: 5504-5514. (Pubitemid 41060827)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.15
, pp. 5504-5514
-
-
Prince, H.M.1
Mileshkin, L.2
Roberts, A.3
Ganju, V.4
Underbill, C.5
Catalane, J.6
Bell, R.7
Seymour, J.F.8
Westerman, D.9
Simmons, P.J.10
Lillie, K.11
Milner, A.D.12
Di Iulio, J.13
Zeldis, J.B.14
Ramsay, R.15
-
24
-
-
33847345109
-
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2
-
DOI 10.1007/s10875-007-9070-6
-
Ferguson GD, Jensen-Pergakes K, Wilkey C, Jhaveri U, Richard N, Verhelle D et al. Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol 2007; 27: 210-220. (Pubitemid 46348725)
-
(2007)
Journal of Clinical Immunology
, vol.27
, Issue.2
, pp. 210-220
-
-
Ferguson, G.D.1
Jensen-Pergakes, K.2
Wilkey, C.3
Jhaveri, U.4
Richard, N.5
Verhelle, D.6
De Parseval, L.M.7
Corral, L.G.8
Xie, W.9
Morris, C.L.10
Brady, H.11
Chan, K.12
-
25
-
-
70349739288
-
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism
-
Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009; 69: 7347-7356.
-
(2009)
Cancer Res
, vol.69
, pp. 7347-7356
-
-
Escoubet-Lozach, L.1
Lin, I.L.2
Jensen-Pergakes, K.3
Brady, H.A.4
Gandhi, A.K.5
Schafer, P.H.6
-
26
-
-
0037097595
-
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications
-
DOI 10.1182/blood.V99.12.4525
-
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-4530. (Pubitemid 34627223)
-
(2002)
Blood
, vol.99
, Issue.12
, pp. 4525-4530
-
-
Mitsiades, N.1
Mitsiades, C.S.2
Poulaki, V.3
Chauhan, D.4
Richardson, P.G.5
Hideshima, T.6
Munshi, N.C.7
Treon, S.P.8
Anderson, K.C.9
-
27
-
-
79955969732
-
IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM
-
Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011; 117: 5157-5165.
-
(2011)
Blood
, Issue.117
, pp. 5157-5165
-
-
Li, S.1
Pal, R.2
Monaghan, S.A.3
Schafer, P.4
Ouyang, H.5
Mapara, M.6
-
28
-
-
77949350034
-
Identification of a primary target of thalidomide teratogenicity
-
Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345-1350.
-
(2010)
Science
, vol.327
, pp. 1345-1350
-
-
Ito, T.1
Ando, H.2
Suzuki, T.3
Ogura, T.4
Hotta, K.5
Imamura, Y.6
-
29
-
-
84869082150
-
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
-
Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326-2335.
-
(2012)
Leukemia
, vol.26
, pp. 2326-2335
-
-
Lopez-Girona, A.1
Mendy, D.2
Ito, T.3
Miller, K.4
Gandhi, A.K.5
Kang, J.6
-
30
-
-
84862152044
-
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
-
Yang Y, Shaffer 3rd AL, Emre NC, Ceribelli M, Zhang M, Wright G et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723-737.
-
(2012)
Cancer Cell
, vol.21
, pp. 723-737
-
-
Yang, Y.1
Shaffer III, A.L.2
Emre, N.C.3
Ceribelli, M.4
Zhang, M.5
Wright, G.6
-
31
-
-
80855156719
-
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
-
Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-479.
-
(2011)
Blood
, vol.118
, pp. 4771-5479
-
-
Zhu, Y.X.1
Braggio, E.2
Shi, C.X.3
Bruins, L.A.4
Schmidt, J.E.5
Van Wier, S.6
-
32
-
-
84876724199
-
Molecular mechanism of action of immunemodulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
-
Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immunemodulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 2012; 54: 683-687.
-
(2012)
Leuk Lymphoma
, vol.54
, pp. 683-687
-
-
Zhu, Y.X.1
Kortuem, K.M.2
Stewart, A.K.3
-
33
-
-
84884983929
-
Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma
-
Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi C-X, Bruins L et al. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. ASH Annual Meeting Abstracts 2012; 120: 194.
-
(2012)
ASH Annual Meeting Abstracts
, vol.120
, pp. 194
-
-
Schuster, S.R.1
Kortuem, K.M.2
Zhu, Y.X.3
Braggio, E.4
Shi, C.-X.5
Bruins, L.6
-
34
-
-
4344693453
-
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
-
DOI 10.1200/JCO.2004.10.052
-
Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269-3276. (Pubitemid 41103682)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.16
, pp. 3269-3276
-
-
Schey, S.A.1
Fields, P.2
Bartlett, J.B.3
Clarke, I.A.4
Ashan, G.5
Knight, R.D.6
Streetly, M.7
Dalgleish, A.G.8
-
35
-
-
40449135275
-
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
-
DOI 10.1111/j.1365-2141.2008.07013.x
-
Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008; 141: 41-51. (Pubitemid 351350609)
-
(2008)
British Journal of Haematology
, vol.141
, Issue.1
, pp. 41-51
-
-
Streetly, M.J.1
Gyertson, K.2
Daniel, Y.3
Zeldis, J.B.4
Kazmi, M.5
Schey, S.A.6
-
36
-
-
73849086725
-
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
-
Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5008-5014.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5008-5014
-
-
Lacy, M.Q.1
Hayman, S.R.2
Gertz, M.A.3
Dispenzieri, A.4
Buadi, F.5
Kumar, S.6
-
37
-
-
78149468560
-
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
-
Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24: 1934-1939.
-
(2010)
Leukemia
, vol.24
, pp. 1934-1939
-
-
Lacy, M.Q.1
Hayman, S.R.2
Gertz, M.A.3
Short, K.D.4
Dispenzieri, A.5
Kumar, S.6
-
38
-
-
84856719479
-
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
-
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149-157.
-
(2012)
Leukemia
, vol.26
, pp. 149-157
-
-
Kumar, S.K.1
Lee, J.H.2
Lahuerta, J.J.3
Morgan, G.4
Richardson, P.G.5
Crowley, J.6
-
39
-
-
80052937408
-
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: Comparison of 2 dosing strategies in dual-refractory disease
-
Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011; 118: 2970-2975.
-
(2011)
Blood
, Issue.118
, pp. 2970-2975
-
-
Lacy, M.Q.1
Allred, J.B.2
Gertz, M.A.3
Hayman, S.R.4
Short, K.D.5
Buadi, F.6
-
40
-
-
79953228454
-
A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib
-
Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Sullivan D et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. ASH Annual Meeting Abstracts 2010; 116: 864.
-
(2010)
ASH Annual Meeting Abstracts
, vol.116
, pp. 864
-
-
Richardson, P.G.1
Siegel, D.2
Baz, R.3
Kelley, S.L.4
Munshi, N.C.5
Sullivan, D.6
-
41
-
-
84857922830
-
Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT) phase 2 results
-
Richardson PG, Siegel DS, Vij R, Hofmeister CC, Jagannath S, Chen C et al. Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT) phase 2 results. ASH Annual Meeting Abstracts 2011; 118: 634.
-
(2011)
ASH Annual Meeting Abstracts
, Issue.118
, pp. 634
-
-
Richardson, P.G.1
Siegel, D.S.2
Vij, R.3
Hofmeister, C.C.4
Jagannath, S.5
Chen, C.6
-
42
-
-
84884702467
-
With or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/ refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT)
-
Abstract 8016
-
Vij RR, Jagannath PG, Siegel S, Baz DS, Srinivasan RC, Larkins S et al. (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/ refractory multiple myeloma (RRMM): outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT). J Clin Oncol 2012; 30: (Abstract 8016).
-
(2012)
J Clin Oncol
, vol.30
-
-
Vij, R.R.1
Jagannath, P.G.2
Siegel, S.3
Baz, D.S.4
Srinivasan, R.C.5
Larkins, S.6
-
43
-
-
79957456049
-
Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02
-
Leleu X, Attal M, Moreau P, Duhamel A, Fermand JP, Michalet M et al. Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02. ASH Annual Meeting Abstracts 2010; 116: 859.
-
(2010)
ASH Annual Meeting Abstracts
, vol.116
, pp. 859
-
-
Leleu, X.1
Attal, M.2
Moreau, P.3
Duhamel, A.4
Fermand, J.P.5
Michalet, M.6
-
44
-
-
84885218048
-
Prolonged overall survival with pomalidomide and dexamethasone in myeloma characterized with end stage disease
-
Leleu X, Roussel M, Arnulf B, Moreau P, Traulle C, Michalet M et al. Prolonged overall survival with pomalidomide and dexamethasone in myeloma characterized with end stage disease. ASH Annual Meeting Abstracts 2012; 120: 2961.
-
(2012)
ASH Annual Meeting Abstracts
, vol.120
, pp. 2961
-
-
Leleu, X.1
Roussel, M.2
Arnulf, B.3
Moreau, P.4
Traulle, C.5
Michalet, M.6
-
45
-
-
84874908368
-
Pomalidomide in Combination with low-dose dexamethasone: Demonstrates a significant progression free survival and overall survival advantage, in relapsed/ refractory MM: A phase 3, multicenter, randomized open-label study
-
Dimopoulos MA, Lacy MQ, Moreau P, Weisel KC, Song KW, Delforge M et al. Pomalidomide in Combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/ refractory MM: a phase 3, multicenter, randomized open-label study. ASH Annual Meeting Abstracts 2012; 120: LBA- 6.
-
(2012)
ASH Annual Meeting Abstracts
, vol.120
-
-
Dimopoulos, M.A.1
Lacy, M.Q.2
Moreau, P.3
Weisel, K.C.4
Song, K.W.5
Delforge, M.6
-
46
-
-
84884221713
-
A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma
-
Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C et al. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 2012; 120: 74.
-
(2012)
ASH Annual Meeting Abstracts
, Issue.120
, pp. 74
-
-
Shah, J.J.1
Stadtmauer, E.A.2
Abonour, R.3
Cohen, A.D.4
Bensinger, W.I.5
Gasparetto, C.6
-
47
-
-
84885211529
-
Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma
-
Abstract 8036
-
Rossi AC, Mark TM, Rodriguez M, Shah M, Quinn R, Pearse R et al. Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30: (Abstract 8036).
-
(2012)
J Clin Oncol
, pp. 30
-
-
Rossi, A.C.1
Mark, T.M.2
Rodriguez, M.3
Shah, M.4
Quinn, R.5
Pearse, R.6
-
48
-
-
84877147624
-
Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed/refractory multiple myeloma
-
Palumbo A, Larocca A, Montefusco V, Rossi D, Carella AM, Mina R et al. Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 2012; 120: 446.
-
(2012)
ASH Annual Meeting Abstracts
, vol.120
, pp. 446
-
-
Palumbo, A.1
Larocca, A.2
Montefusco, V.3
Rossi, D.4
Carella, A.M.5
Mina, R.6
-
49
-
-
41149168649
-
Lenalidomide for the treatment of B-cell malignancies
-
Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544-1552.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1544-1552
-
-
Chanan-Khan, A.A.1
Cheson, B.D.2
-
50
-
-
35748947186
-
Lenalidomide in Combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma
-
Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T et al. Lenalidomide in Combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts 2006; 108: 3553.
-
(2006)
ASH Annual Meeting Abstracts
, vol.108
, pp. 3553
-
-
Wang, M.1
Knight, R.2
Dimopoulos, M.3
Siegel, D.4
Rajkumar, S.V.5
Facon, T.6
-
51
-
-
84859646589
-
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy
-
Sinha S, Lacy M, Mikhael J, Hayman S, Buadi F, Detweiler-Short K et al. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia 2012; 26: 839-841.
-
(2012)
Leukemia
, vol.26
, pp. 839-841
-
-
Sinha, S.1
Lacy, M.2
Mikhael, J.3
Hayman, S.4
Buadi, F.5
Detweiler-Short, K.6
-
52
-
-
77956259865
-
Importance of achieving a complete response in multiple myeloma, and the impact of novel agents
-
Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. Journal Clin Oncol 2010; 28: 2612-2624.
-
(2010)
Journal Clin Oncol
, vol.28
, pp. 2612-2624
-
-
Chanan-Khan, A.A.1
Giralt, S.2
-
53
-
-
41949130070
-
Improved survival in multiple myeloma and the impact of novel therapies
-
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
-
(2008)
Blood
, vol.111
, pp. 2516-2520
-
-
Kumar, S.K.1
Rajkumar, S.V.2
Dispenzieri, A.3
Lacy, M.Q.4
Hayman, S.R.5
Buadi, F.K.6
-
54
-
-
67349240834
-
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS) an analysis of the Greek Myeloma Study Group (GMSG)
-
Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152-1157.
-
(2009)
Leukemia
, vol.23
, pp. 1152-1157
-
-
Kastritis, E.1
Zervas, K.2
Symeonidis, A.3
Terpos, E.4
Delimbassi, S.5
Anagnostopoulos, N.6
-
55
-
-
3242763046
-
Extramedullary multiple myeloma escapes the effect of thalidomide
-
Rosinol L, Cibeira MT, Blade J, Esteve J, Aymerich M, Rozman M et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832-836. (Pubitemid 38981343)
-
(2004)
Haematologica
, vol.89
, Issue.7
, pp. 832-836
-
-
Rosinol, L.1
Cibeira, M.T.2
Blade, J.3
Esteve, J.4
Aymerich, M.5
Rozman, M.6
Segarra, M.7
Cid, M.C.8
Filella, X.9
Montserrat, E.10
-
56
-
-
77951882321
-
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients
-
Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010; 21: 325-3230.
-
(2010)
Ann Oncol
, Issue.21
, pp. 325-3230
-
-
Varettoni, M.1
Corso, A.2
Pica, G.3
Mangiacavalli, S.4
Pascutto, C.5
Lazzarino, M.6
-
57
-
-
79958127449
-
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
-
Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011; 25: 906-908.
-
(2011)
Leukemia
, Issue.25
, pp. 906-908
-
-
Short, K.D.1
Rajkumar, S.V.2
Larson, D.3
Buadi, F.4
Hayman, S.5
Dispenzieri, A.6
|